NCM · Biotechnology

ProKidney Corp. (PROK) Stock

$1.56 +3.67% NCM: PROK Healthcare

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments.

Valuation

MetricValue
Price$1.56
Market Cap$522.87M
P/E Ratio-2.73
P/B Ratio-0.21
P/S Ratio567.36
EPS (TTM)$-0.73
52-Week High$3.55
52-Week Low$1.45
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE7.40%
ROA-25.56%
ROCE-63.16%
Gross Margin-16500.00%
Operating Margin-16500.00%
Net Margin-84.18%
Debt/Equity0.00
Current Ratio9.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$1.0M
Operating Profit$-55.0M$-153.0M$-152.0M$-184.0M$-165.0M
Net Profit$-55.0M$-108.0M$-35.0M$-61.0M$-69.0M
EPS$-1.73$-1.76$-0.57$-0.62$-0.52
Op Margin———-241679.0%-18477.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$40.0M$518.0M$421.0M$441.0M$336.0M
Total Liabilities$13.0M$13.0M$29.0M$39.0M$35.0M
Cash$21.0M$490.0M$61.0M$99.0M$109.0M
Borrowings$1.0M$2.0M$4.0M$3.0M$4.0M

Latest News

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path Insider Monkey · Jun 17, 2026 Identiv And Two Other Penny Stocks To Watch Closely Simply Wall St. · Jun 5, 2026 ProKidney Appoints Kenneth Locke as Chief Technical Officer GlobeNewswire · Jun 2, 2026 ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates Zacks · May 15, 2026 ProKidney Reports First Quarter 2026 Financial Results and Business Highlights GlobeNewswire · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-50.0M$-77.0M$-90.0M$-126.0M$-120.0M
Investing Cash Flow$-10.0M$-4.0M$-364.0M$-9.0M$89.0M
Financing Cash Flow$0$543.0M$-9.0M$0$0
Net Cash Flow$16.0M$470.0M$-430.0M$38.0M$9.0M
Free Cash Flow$-55.0M$-79.0M$-124.0M$-156.0M$-135.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.35
EV / EBITDA-2.79
FCF Yield-25.82%
Quick Ratio9.06
Interest Coverage-8871.16
Return 1Y-52.80%
Return 3Y-86.65%
Return 5Y-84.52%

Ownership

Insiders Held47.30%
Institutions Held24.40%
Institutions Float Held46.30%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC12,341,2662026-03-31
Morgan Stanley8,955,9672026-03-31
Millennium Management Llc2,271,5772026-03-31
Bleichroeder LP2,000,0002026-03-31
Hennion & Walsh Asset Management, Inc.1,847,7492026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCAX $27.81 +2.92% -7.37 $1.52B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%
NBTXNanobiotix S.A. $40.18 +1.21% -68.71 $2.03B 0.00%
PRME $3.01 +2.03% -3.33 $543.66M 0.00%

About ProKidney Corp.

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

ProKidney Corp. is led by CEO Bruce Culleton, employs 204 people, headquartered in US, publicly traded since 2021.

ProKidney Corp. (PROK) stock trades at $1.56 with a market capitalization of $522.87M. The stock is valued at a price-to-earnings (P/E) ratio of -2.73, price-to-book of -0.21, price-to-sales of 567.36. Over the past 52 weeks the stock has ranged between $1.45 and $3.55, and currently trades 56.1% below its 52-week high.

On profitability, ProKidney Corp. generates a return on equity (ROE) of 7.40%, return on capital employed of -63.16%, an operating margin of -16500.00%, a net profit margin of -84.18%.

Official website: www.prokidney.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides